An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) announced its participation in the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on September 10. CEO and CFO Ying Huang will represent the company at 8:45 a.m. Eastern Time. Investors can access the conference webcast on the Legend Biotech website. The company focuses on developing novel cell therapies for oncology, notably its lead candidate cilta-cel for multiple myeloma, currently in registrational clinical trials. With over 900 employees across the U.S., China, and Europe, Legend Biotech is poised to advance innovative treatments.
Positive
None.
Negative
None.
SOMERSET, N.J.--(BUSINESS WIRE)--
Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Friday, September 10. Ying Huang, Chief Executive Officer and Chief Financial Officer, will represent the Company in a session scheduled at 8:45 a.m. (Eastern Time).
The webcast will be available to investors and other interested parties by accessing the Legend Biotech website at https://investors.legendbiotech.com.
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 900 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, cilta-cel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.
